Frank Vinluan

Business journalist in Research Triangle Park on @Xconomy's biotech team covering pharma, medtech, agtech. 71% free throw shooter. Genesis: Album 9, track 11.

Categories
N/A
Content Types
N/A
More Information
Location|Languages
Publications
N/A

Published Content

394
xconomy.com
Article
Xconomy: Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials
May, 9 2019
xconomy.com
Article
Xconomy: At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
May, 3 2019
xconomy.com
Article
Xconomy: Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
April, 26 2019
xconomy.com
Article
Xconomy: Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache
April, 23 2019
xconomy.com
Article
Xconomy: Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More
March, 15 2019
xconomy.com
Article
Xconomy: Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
February, 22 2019
xconomy.com
Article
Xconomy: Merck Scooping Up Cancer Drug Developer Immune Design for $300M
February, 21 2019
xconomy.com
Article
Xconomy: Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
February, 1 2019
xconomy.com
Article
Xconomy: Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
January, 11 2019
xconomy.com
Article
Xconomy: Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
January, 9 2019
xconomy.com
Article
Xconomy: Genentech, Adaptive Bio Join Forces on Personalized Cancer Drugs R&D
January, 4 2019
xconomy.com
Article
Xconomy: Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More
December, 14 2018
xconomy.com
Article
Xconomy: Farm Startup Bowery Lands $90M to Take Indoor-Grown Greens National
December, 12 2018
xconomy.com
Article
Xconomy: SuperNus ADHD Drug to Head to FDA, But Is It Better Than a Generic?
December, 6 2018
xconomy.com
Article
Xconomy: How Blockchain Is Finding a Place at Your Thanksgiving Table
November, 20 2018
xconomy.com
Article
Xconomy: Plant-Based Burger Maker Beyond Meat Cooks Up Plans for an IPO
November, 19 2018
xconomy.com
Article
Xconomy: Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
November, 16 2018
xconomy.com
Article
Xconomy: Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
October, 26 2018
xconomy.com
Article
Xconomy: Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron
October, 24 2018
xconomy.com
Article
Xconomy: AbbVie Commits $100M to Morphic in Fibrosis Drug R&D Alliance
October, 18 2018
xconomy.com
Article
Xconomy: Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals
October, 17 2018
xconomy.com
Article
Xconomy: Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy
October, 11 2018
xconomy.com
Article
Xconomy: Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More
October, 5 2018
xconomy.com
Article
Xconomy: Pivot Bio Gets $70M, Led by Bill Gates’s Fund, to Replace Fertilizer
October, 2 2018
xconomy.com
Article
Xconomy: VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic
October, 1 2018
xconomy.com
Article
Xconomy: Six Life Science Firms Close Q3 with an IPO, More Are on the Way
September, 28 2018
xconomy.com
Article
Xconomy: Eli Lilly Strikes Deal for Diabetes Pill to Gain on Novo Nordisk
September, 27 2018
xconomy.com
Article
Xconomy: Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s
September, 14 2018
xconomy.com
Article
Xconomy: Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More
September, 14 2018
xconomy.com
Article
Xconomy: Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More
August, 24 2018
xconomy.com
Article
Xconomy: Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
August, 22 2018
xconomy.com
Article
Xconomy: Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More
July, 13 2018
xconomy.com
Article
Xconomy: CTI BioPharma’s Non-Hodgkin Lymphoma Drug Fails Study, Shares Sink
July, 9 2018
xconomy.com
Article
Xconomy: Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test
June, 29 2018
xconomy.com
Article
Xconomy: IPO Wave Rolls On as Five Life Science Firms Haul in $651M
June, 28 2018
xconomy.com
Article
Xconomy: Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come
June, 26 2018
xconomy.com
Article
Xconomy: Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More
June, 22 2018
xconomy.com
Article
Xconomy: Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
June, 21 2018
xconomy.com
Article
Xconomy: What’s Hot in Seattle Biotech: Tech, Life Sciences Convergence & More
June, 19 2018
xconomy.com
Article
Xconomy: Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches
June, 15 2018
xconomy.com
Article
Xconomy: Allergan’s Migraine-Reducing Pill Hits Study Goals, Heads to Phase 3
June, 11 2018
xconomy.com
Article
Xconomy: Diagnostics Developer Nanopore Wins Agtech and Food Startup Showcase
April, 30 2018
xconomy.com
Article
Xconomy: Bio Roundup: CRISPR Tests, Parkinson’s Questions, Opioid Bills & More
April, 27 2018
xconomy.com
Article
Xconomy: DARPA Enlists Insects in R&D Effort to Protect the Food Supply
April, 25 2018
xconomy.com
Article
Xconomy: Virta Health Hauls in $45M to Expand “Diabetes-Reversing” Software
April, 4 2018
xconomy.com
Article
Xconomy: Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More
March, 30 2018
xconomy.com
Article
Xconomy: Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies
March, 29 2018
xconomy.com
Article
Xconomy: Rheos Medicines Launches, Backed by $60M for Immunometabolism R&D
March, 22 2018
xconomy.com
Article
Xconomy: Alder BioPharma’s Schatzman Steps Down as CEO by “Mutual Decision”
March, 20 2018
xconomy.com
Article
Xconomy: Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More
March, 16 2018
Authorship Stats
2Sites394Projects203,532Words
About
Frank Vinluan is a writer who has produced content for xconomy.com and xconomy.com
Key Phrases
Fda Approval, Clinical Trial, Bio Roundup, Eli Lilly, Clinical Trials, Gene Therapy, Migraine Drug, Million Shares, Drug Prices, Cancer Drug
© ClearVoice, Inc.